Guangzhou Baiyunshan Pharmaceutical Holdings announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical, has had its dexamethasone sodium phosphate injection, one milliliter to five milligrams, pass the generic drug quality and efficacy consistency evaluation. The drug is mainly used for allergic and autoimmune inflammatory diseases. Tianxin Pharmaceutical submitted the application in December 2024. According to Menet data, in 2025, sales of this specification product in domestic urban and county-level public hospitals, as well as urban and online pharmacies, reached 236 million yuan. The company invested approximately 3.17 million yuan in research and development for this project. In 2025, Tianxin Pharmaceutical's sales revenue from this product was 2.84 million yuan. The company stated that passing the consistency evaluation will help enhance the product's market competitiveness, but there is uncertainty in production and sales.
Guangzhou Baiyunshan Pharmaceutical Holdings Co LtdSubsidiary's dexamethasone injection passes generic drug consistency evaluation, enhancing market competitiveness.
Tianxin Pharmaceutical's product passes consistency evaluation, directly benefiting its market position.